Superior Peptide


MK-677 Oral HGH Secretagogue

Results 1 to 4 of 4
  1. #1
    Senior Member
    BOARD REP
    JJB1's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    USA
    Posts
    1,702
    Rep Points
    2298579

    Thumbs up MK-677 Oral HGH Secretagogue

    MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.


    AuthorsMurphy MG, et al. Show all Journal
    J Clin Endocrinol Metab. 1998 Feb;83(2):320-5.

    Abstract



    The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic patients. A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism. Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods. During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily. There was a 14- to 21-day washout interval between periods. During the first week of caloric restriction (i.e. diet alone), daily nitrogen losses were similar for both treatment groups (mean +/- SE; MK-677 group -2.67 +/- 0.40 g/day vs. placebo group -2.83 +/- 0.26 g/day). During the second week (diet and study drug), mean daily nitrogen balance was 0.31 +/- 0.21 g/day in the MK-677 treatment group compared with -1.48 +/- 0.21 g/day in the placebo group (P < 0.01). MK-677 improved nitrogen balance integrated over the 7 days of treatment; area under the curve day 8-14 nitrogen balance response was +2.69 +/- 5.0 (SE) for MK-677 and -8.97 +/- 5.26 g.day for placebo (P < 0.001). MK-677 produced a peak GH response of 55.9 +/- 31.7 micrograms/L after single dose (day 1 of treatment) and 22.6 +/- 9.3 micrograms/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 micrograms/L (treatment day 7). Following the initial 7-day caloric restriction, insulin-like growth factor-I (IGF-I) declined from 232 +/- 25 to 186 +/- 19 ng/mL in the MK-677 group and from 236 +/- 19 to 174 +/- 23 ng/mL in the placebo group. Mean IGF-I concentration increased significantly during MK-677 to 264 +/- 31 ng/mL (mean for the last 5 days of treatment) compared with 188 +/- 19 ng/mL with placebo (P < 0.01). No significant difference in IGF binding protein-2 was found between the MK-677 and placebo treatments. However, the mean in IGF binding protein-3 for the last 5 days of MK-677 treatment was also significantly increased to 3273 +/- 330 ng/mL (mean +/- SE) compared with placebo 2604 +/- 253 ng/mL (P < 0.01). Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo. MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences. In conclusion, MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic because of certain acute or chronic disease states, it may be useful in treating catabolic conditions.
    SUPERIOR PEPTIDE USA
    BOGO CODE: BOGOJJB1
    Use Code: JJ25PERCOFF for 25% off
    on your next SuperiorPeptide.com
    purchase
    SUPERIOR PEPTlDE CANADA
    SUPERIOR PEPTlDE EUROPE



  2. #2
    Senior Member
    BOARD REP
    JJB1's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    USA
    Posts
    1,702
    Rep Points
    2298579

    MK-677 is a ghrelin memetic like GHRP6 so perfect for the bulk cycle I'm on.


    Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.


    AuthorsNass R, et al. Show all Journal
    Ann Intern Med. 2008 Nov 4;149(9):601-11.


    Affiliation
    Comment in
    Ann Intern Med. 2009 May 5;150(9):654-5; author reply 655.
    Ann Intern Med. 2008 Nov 4;149(9):677-9.
    Ann Intern Med. 2009 May 5;150(9):653-4; author reply 655.
    Ann Intern Med. 2009 May 5;150(9):654; author reply 655.
    Summary for patients in
    Ann Intern Med. 2008 Nov 4;149(9):I-36.
    Abstract
    BACKGROUND: Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of many factors, and its etiologic role needs to be demonstrated.


    OBJECTIVE: To determine whether MK-677, an oral ghrelin mimetic, increases growth hormone secretion into the young-adult range without serious adverse effects, prevents the decline of fat-free mass, and decreases abdominal visceral fat in healthy older adults.


    DESIGN: 2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.


    SETTING: General clinical research center study performed at a university hospital.


    PARTICIPANTS: 65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.


    INTERVENTION: Oral administration of MK-677, 25 mg, or placebo once daily.


    MEASUREMENTS: Growth hormone and insulin-like growth factor I levels. Fat-free mass and abdominal visceral fat were the primary end points after 1 year of treatment. Other end points were body weight, fat mass, insulin sensitivity, lipid and cortisol levels, bone mineral density, limb lean and fat mass, isokinetic strength, function, and quality of life. All end points were assessed at baseline and every 6 months.


    RESULTS: Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects. Mean fat-free mass decreased in the placebo group but increased in the MK-677 group (change, -0.5 kg [95% CI, -1.1 to 0.2 kg] vs. 1.1 kg [CI, 0.7 to 1.5 kg], respectively; P < 0.001), as did body cell mass, as reflected by intracellular water (change, -1.0 kg [CI, -2.1 to 0.2 kg] vs. 0.8 kg [CI, -0.1 to 1.6 kg], respectively; P = 0.021). No significant differences were observed in abdominal visceral fat or total fat mass; however, the average increase in limb fat was greater in the MK-677 group than the placebo group (1.1 kg vs. 0.24 kg; P = 0.001). Body weight increased 0.8 kg (CI, -0.3 to 1.8 kg) in the placebo group and 2.7 kg (CI, 2.0 to 3.5 kg) in the MK-677 group (P = 0.003). Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased. The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. Low-density lipoprotein cholesterol levels decreased in the MK-677 group relative to baseline values (change, -0.14 mmol/L [CI, -0.27 to -0.01 mmol/L]; -5.4 mg/dL [CI, -10.4 to -0.4 mg/dL]; P = 0.026); no differences between groups were observed in total or high-density lipoprotein cholesterol levels. Cortisol levels increased 47 nmol/L (CI, 28 to 71 nmol/L (1.7 microg/dL [CI, 1.0 to 2.6 microg/dL]) in MK-677 recipients (P = 0.020). Changes in bone mineral density consistent with increased bone remodeling occurred in MK-677 recipients. Increased fat-free mass did not result in changes in strength or function. Two-year exploratory analyses confirmed the 1-year results.


    LIMITATION: Study power (duration and participant number) was insufficient to evaluate functional end points in healthy elderly persons.


    CONCLUSION: Over 12 months, the ghrelin mimetic MK-677 enhanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated. Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicated.
    SUPERIOR PEPTIDE USA
    BOGO CODE: BOGOJJB1
    Use Code: JJ25PERCOFF for 25% off
    on your next SuperiorPeptide.com
    purchase
    SUPERIOR PEPTlDE CANADA
    SUPERIOR PEPTlDE EUROPE



  3. #3
    Senior Member
    BOARD REP
    JJB1's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    USA
    Posts
    1,702
    Rep Points
    2298579

    Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.


    AuthorsCopinschi G, et al. Show all Journal
    Neuroendocrinology. 1997 Oct;66(4):278-86.


    Affiliation
    Abstract
    Previous studies have indicated the existence of common mechanisms regulating sleep and somatotropic activity. In the present study, we investigated the effects of prolonged treatment with a novel, orally active, growth hormone secretagogue (MK-677) on sleep quality in healthy young and older adults. Eight young subjects (18-30 years) followed a double-blind, placebo-controlled, three-period crossover design. Each subject participated in three 7-day treatment periods (with bedtime drug administration), presented in random (Latin square) order, and separated by at least 14 days. Doses were 5 and 25 mg MK-677 and matching placebo. Six older subjects, ages 65-71 years, each participated in two 14-day treatment periods (with bedtime drug administration) separated by a 14-day washout. Doses were 2 and 25 mg MK-677 during the first and second periods, respectively. Baseline sleep and hormonal data were obtained on the 2 days preceding the beginning of the first 14-day treatment period. In young subjects, high-dose MK-677 treatment resulted in an approximately 50% increase in the duration of stage IV and in a more than 20% increase in REM sleep as compared to placebo (p < 0.05). The frequency of deviations from normal sleep decreased from 42% under placebo to 8% under high-dose MK-677 (p < 0.03). In older adults, treatment with MK-677 was associated with a nearly 50% increase in REM sleep (p < 0.05) and a decrease in REM latency (p < 0.02). The frequency of deviations from normal sleep also decreased (p < 0.02). The present findings suggest that MK-677 may simultaneously improve sleep quality and correct the relative hyposomatotropism of senescence.
    SUPERIOR PEPTIDE USA
    BOGO CODE: BOGOJJB1
    Use Code: JJ25PERCOFF for 25% off
    on your next SuperiorPeptide.com
    purchase
    SUPERIOR PEPTlDE CANADA
    SUPERIOR PEPTlDE EUROPE



  4. #4
    Senior Member
    BOARD REP
    JJB1's Avatar


    Join Date
    Apr 2014
    Gender
    Male
    Location
    USA
    Posts
    1,702
    Rep Points
    2298579

    Here is a post from russianstar at the end of his MK-677 log:


    "I finished the cycle 4lbs up, feeling stronger, sleeping better, perfect skin, this is one of my favourite supps.. i will post up a full review shortly, but i will be running this now at 50mg ed next time, it felt like 4iu of gh easily.. was even getting numb fingers."
    SUPERIOR PEPTIDE USA
    BOGO CODE: BOGOJJB1
    Use Code: JJ25PERCOFF for 25% off
    on your next SuperiorPeptide.com
    purchase
    SUPERIOR PEPTlDE CANADA
    SUPERIOR PEPTlDE EUROPE



Similar Threads

  1. Replies: 0
    Last Post: 06-21-2011, 05:17 PM
  2. Secretagogue-One
    By N_I_C_K in forum Supplements
    Replies: 7
    Last Post: 11-05-2010, 03:58 PM
  3. Whats witht the oral tren and oral primo???
    By DaBeast25 in forum Anabolic Zone
    Replies: 3
    Last Post: 04-02-2010, 04:10 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
-->